NEW YORK, Feb. 20, 2018 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of the securities of Ballard Power Systems Inc. (NASDAQ:BLDP) between September 30, 2016 and January 25, 2018, both dates inclusive (“Class Period”). The lawsuit seeks to recover damages for Ballard investors under the federal securities laws.
To join the Ballard class action, go to http://www.rosenlegal.com/cases-1277.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Ballard overstated the operations of its China-based partners Broad Ocean and Synergy; (2) there are no demonstration lines operating in Guangdong and no bus lines are in service in Sanshui or Yunfu; (3) Foshan has produced far fewer buses than Ballard has indicated, and only 11 are licensed; and (4) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1277.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Daniel Sadeh of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Daniel Sadeh, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



